{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:44:15Z","timestamp":1740980655043,"version":"3.38.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mjt.0b013e31820543d7","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T08:17:01Z","timestamp":1297412221000},"page":"e167-e171","source":"Crossref","is-referenced-by-count":0,"title":["Sepsis"],"prefix":"10.1097","volume":"19","author":[{"given":"Anahat","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":". Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"issue":"Suppl","key":"R2-13-20210202","first-page":"e28","article-title":". Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.","volume":"136","author":"Bone","year":"2009","journal-title":"Chest"},{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM199102143240701","article-title":". Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.","volume":"324","author":"Ziegler","year":"1991","journal-title":"N Engl J Med"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.1991.03470080067031","article-title":". A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group.","volume":"266","author":"Greenman","year":"1991","journal-title":"JAMA"},{"key":"R5-13-20210202","first-page":"58","article-title":"Antiendotoxin antibodies: a dead end Ann Intern Med.","volume":"121","author":"Cross","year":"1994","journal-title":""},{"key":"R6-13-20210202","first-page":"282","article-title":"Mediator modulation therapy of severe sepsis and septic shock: does it work Crit Care Med.","volume":"32","author":"Dellinger","year":"2004","journal-title":""},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":". Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis.","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/CCM.0b013e3181c9cbb5","article-title":"Regulation of inflammation by the protein C system.","volume":"38","author":"Weiler","year":"2010","journal-title":"Crit Care Med"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"R14-13-20210202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses.","volume":"22","author":"Morgensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"R15-13-20210202","first-page":"3723","article-title":"Stress molecules in sepsis and systemic inflammatory response syndrome.","volume":"581","author":"Adib-Conquy","year":"2007","journal-title":"GEBS Lett"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccc.2009.08.002","article-title":"The pathophysiology of septic shock.","volume":"25","author":"Nduka","year":"2009","journal-title":"Crit Care Clin"},{"key":"R17-13-20210202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","article-title":"; Eritoran Sepsis Study Group. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis.","volume":"38","author":"Tidswell","year":"2010","journal-title":"Crit Care Med"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00134-007-0934-2","article-title":". Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.","volume":"34","author":"Dellinger","year":"2008","journal-title":"Intensive Care Med"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":". Early goal-directed therapy in the treatment of severe sepsis and septic shock.","volume":"345","author":"Rivers","year":"2001","journal-title":"N Engl J Med"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jcem-59-6-1143","article-title":". Etomidate suppresses adrenocortical function by inhibition of 11 betahydroxylation.","volume":"59","author":"de Jong","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/cc4979","article-title":"The incidence of relative adrenal insufficiency in patients with septic shock after the administration of etomidate.","volume":"10","author":"Mohammad","year":"2006","journal-title":"Crit Care"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/01.CCM.0000259465.92018.6E","article-title":". Adrenal function in sepsis: the retrospective Corticus cohort study.","volume":"35","author":"Lipiner-Friedman","year":"2007","journal-title":"Crit Care Med"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/ALN.0b013e3181ae63d1","article-title":". Methoxy carbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.","volume":"111","author":"Cotton","year":"2009","journal-title":"Anesthesiology"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00134-009-1520-6","article-title":"PRO: hydroxyethylstarch can be safely used in the intensive care patient - the renal debate.","volume":"35","author":"Boldt","year":"2009","journal-title":"Intensive Care Med"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(00)04211-2","article-title":". Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomized study.","volume":"357","author":"Schortgen","year":"2001","journal-title":"Lancet"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa070716","article-title":". Intensive insulin therapy and pentastarch resuscitation in severe sepsis.","volume":"358","author":"Brunkhorst","year":"2008","journal-title":"N Engl J Med"},{"key":"R28-13-20210202","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/cc7726","article-title":". Hydroxylethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model.","volume":"13","author":"Huter","year":"2009","journal-title":"Crit Care"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31820543d7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T15:13:01Z","timestamp":1740928381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201211000-00013"}},"subtitle":["A Review of Therapeutics and Considerations for Anesthesiologists"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31820543d7","relation":{},"ISSN":["1075-2765"],"issn-type":[{"type":"print","value":"1075-2765"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}